News

Video

Driven by Experience: How a Caregiver Became an MPN Advocate

Fact checked by:

An MPN advocate used his personal experiences to inform his dedication to patient-centered research and support programs for patients.

An advocate’s personal connection to cancer has shaped his approach to providing support to patients with myeloproliferative neoplasms (MPNs).

Richard Winneker, a patient advocate for the MPN Research Foundation, recalled his time as a caregiver to his son who had acute lymphoblastic leukemia as a child. He said that this experience has shaped his approach to research and the understanding of cancer’s impact on patients and families.

CURE sat down with Winneker to learn about how his caregiver experience has formed how he advocates for patients with MPNs through research and beyond. For example, he recalls a pivotal moment in his work with the MPN Research Foundation, for which he helped with a patient-focused drug development meeting.

Transcript:

I'll start back with the fact that I had a son — I have a son who had acute lymphoblastic leukemia, so I brought the caregiver experience. I think just saying that word when your child has a cancer probably isn't enough to explain how traumatic it can be, and I've carried that with me through my entire research life.

But I would say the greatest impact that I've experienced during my time at the MPN Research Foundation was when we held, in 2019, an externally led, patient-focused drug development meeting. And that was a meeting where we brought together patients to really talk to representatives of the FDA and pharmaceutical companies about the burden of their disease, what their — what their concerns were and it really opened my eyes to — to how heterogeneous and how difficulty it can be living with these diseases.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content